Sascha David Selected Research

TIE-2 Receptor (Receptor, TIE 2)

3/2016	Gene control of tyrosine kinase TIE2 and vascular manifestations of infections.
6/2012	Impaired function of the Tie-2 receptor contributes to vascular leakage and lethality in anthrax.
5/2012	Angiopoietin-2 levels predict mortality in CKD patients.
8/2011	Acute administration of recombinant Angiopoietin-1 ameliorates multiple-organ dysfunction syndrome and improves survival in murine sepsis.
1/2011	The synthetic tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis.
1/2008	Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sascha David Research Topics

Disease

23	Sepsis (Septicemia) 12/2022 - 01/2008
13	Inflammation (Inflammations) 12/2021 - 01/2008
12	Septic Shock (Toxic Shock Syndrome) 12/2022 - 01/2017
10	Critical Illness (Critically Ill) 02/2022 - 01/2008
10	COVID-19 01/2022 - 01/2020
9	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 02/2022 - 11/2018
6	Infections 12/2021 - 07/2009
6	Endotoxemia 01/2021 - 01/2009
5	Acute Kidney Injury (Acute Renal Failure) 02/2022 - 03/2010
5	Shock 01/2022 - 11/2012
4	Mesenteric Ischemia 01/2022 - 02/2020
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 05/2009
4	Hypertension (High Blood Pressure) 10/2014 - 08/2009
4	Chronic Renal Insufficiency 04/2011 - 04/2008
4	Atherosclerosis 04/2011 - 05/2009
3	Lung Injury 01/2021 - 06/2011
3	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 12/2019 - 11/2018
3	Body Weight (Weight, Body) 01/2019 - 04/2008
3	Multiple Organ Failure (MODS) 01/2012 - 03/2010
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022 - 01/2021
2	Human Influenza (Influenza) 01/2022 - 01/2021
2	Lymphopenia (Lymphocytopenia) 12/2021 - 01/2021
2	Cytokine Release Syndrome 12/2021 - 01/2020
2	Heart Failure 10/2021 - 08/2020
2	Pneumonia (Pneumonitis) 02/2021 - 01/2021
2	Hemorrhage 01/2021 - 01/2020
2	Acute Liver Failure (Fulminant Hepatic Failure) 08/2020 - 10/2019
2	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020 - 12/2015
2	Disease Progression 01/2020 - 01/2015
2	Neoplasms (Cancer) 01/2014 - 09/2008
2	Coronary Disease (Coronary Heart Disease) 05/2012 - 05/2009
2	Essential Hypertension 03/2010 - 08/2009
1	Soft Tissue Infections 02/2022
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022
1	Ischemia 01/2022
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2022
1	Myocarditis (Carditis) 10/2021
1	Thrombotic Microangiopathies 10/2021
1	Bacterial Pneumonia 02/2021
1	Heart Diseases (Heart Disease) 01/2021

Drug/Important Bio-Agent (IBA)

21	Angiopoietin-2IBA 12/2021 - 01/2008
10	CytokinesIBA 12/2021 - 01/2009
9	Biomarkers (Surrogate Marker)IBA 08/2020 - 01/2008
7	Norepinephrine (Noradrenaline)FDA LinkGeneric 12/2022 - 10/2018
7	Proteins (Proteins, Gene)FDA Link 12/2021 - 07/2009
6	TIE-2 Receptor (Receptor, TIE 2)IBA 03/2016 - 01/2008
6	Angiopoietin-1IBA 05/2012 - 01/2008
5	AngiopoietinsIBA 01/2016 - 01/2008
4	Immunoglobulin G (IgG)IBA 12/2021 - 01/2020
4	LigandsIBA 03/2016 - 01/2008
3	Immunoglobulins (Immunoglobulin)IBA 02/2022 - 01/2021
3	Chimeric Antigen ReceptorsIBA 01/2022 - 01/2020
3	Peptides (Polypeptides)IBA 11/2019 - 01/2011
2	FibrinIBA 01/2022 - 11/2019
2	AntibodiesIBA 12/2021 - 01/2021
2	EnzymesIBA 01/2021 - 09/2008
2	MicroRNAs (MicroRNA)IBA 01/2021 - 01/2021
2	pro-brain natriuretic peptide (1-76)IBA 08/2020 - 04/2008
2	Metalloproteases (Metalloproteinases)IBA 01/2020 - 01/2018
2	Pharmaceutical PreparationsIBA 07/2015 - 01/2011
2	C-Reactive ProteinIBA 05/2012 - 07/2009
2	Oxygen (Dioxygen)IBA 10/2011 - 01/2008
2	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 06/2011 - 01/2011
2	VasculotideIBA 06/2011 - 01/2011
2	Pravastatin (Pravachol)FDA LinkGeneric 03/2010 - 08/2009
2	olmesartanIBA 03/2010 - 08/2009
2	Angiotensin Receptor AntagonistsIBA 03/2010 - 08/2009
1	Intravenous Immunoglobulins (IVIG)FDA Link 02/2022
1	BilirubinIBA 01/2022
1	Fibrinogen (Factor I)FDA Link 01/2022
1	Plasminogen Activators (Plasminogen Activator)IBA 01/2022
1	Factor XII (Hageman Factor)IBA 01/2022
1	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2022
1	Ketamine FDA LinkGeneric 01/2022
1	KaolinIBA 01/2022
1	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)IBA 01/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2022
1	Blood Proteins (Serum Proteins)IBA 12/2021
1	GlucuronidaseIBA 12/2021
1	Pathogen-Associated Molecular Pattern MoleculesIBA 12/2021
1	bifonazoleIBA 12/2021
1	Immunoglobulin M (IgM)IBA 12/2021
1	Immunoglobulin A (IgA)IBA 12/2021
1	Heparitin Sulfate (Heparan Sulfate)IBA 12/2021
1	Complement System Proteins (Complement)IBA 10/2021
1	Clonidine (ST 155)FDA LinkGeneric 08/2021
1	Interleukin-6 (Interleukin 6)IBA 02/2021
1	Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA 02/2021
1	Antiviral Agents (Antivirals)IBA 01/2021

Therapy/Procedure

13	Therapeutics 12/2022 - 08/2009
11	Plasma Exchange 12/2022 - 01/2012
5	Extracorporeal Membrane Oxygenation 01/2022 - 01/2019
4	Critical Care (Surgical Intensive Care) 11/2020 - 01/2010
4	Punctures 01/2020 - 01/2011
4	Ligation 01/2020 - 01/2011
3	Renal Dialysis (Hemodialysis) 01/2015 - 07/2010
2	Length of Stay 02/2022 - 01/2021
2	Drug Therapy (Chemotherapy) 10/2019 - 07/2009
2	Bone Marrow Transplantation (Transplantation, Bone Marrow) 10/2019 - 12/2015
1	Controlled Hypotension 08/2021